The trial was the first report of PARPi response in patients with BC with somatic BRCA1/2 mutations, and now Olaparib is a category 2b NCCN (National Comprehensive Cancer Network) guideline recommendation for treatment in metastatic disease, any subtype [70]. This evidence concerns the gene BRCA1 and metastatic neoplasm.